Patent Settlements in the Pharmaceutical Industry: Reading the Tea Leaves of the Supreme Court Argument

Patent Settlements in the Pharmaceutical Industry: Reading the Tea Leaves of the Supreme Court Argument

Thursday, March 28, 2013

• 12:00 – 1:00 pm EST

To register, please click here.

McDermott Will & Emery is pleased to present another complimentary webcast in its regular "Life Sciences: Understanding Opportunities and Challenges for Improved Business Results" series.  This webcast will focus on an analysis of the oral argument before the Supreme Court of the United States on Monday, March 25, 2013, in the case regarding the U.S. Court of Appeals for the Eleventh Circuit’s decision to uphold the settlement in the so-called Androgel case, which involved a so-called "reverse payment.”  The outcome of this case will have profound implications for both branded and generic companies as they consider whether to litigate or settle — and how to settle — "bet the company" patent litigation.

Our distinguished panel will dissect the oral argument before the Supreme Court and forecast the Court's likely analysis of the critical issues.   

McDermott Speakers 

• M. Miller Baker, Partner
• Jeffrey W. Brennan, Partner, Former Head of the FTC's Health Care Division
• William G. Gaede, Partner

Moderator

• Glenn M. Engelmann, Senior Counsel, Former AstraZeneca U.S. General Counsel

For more information, please contact McDermott Events.